DiaMedica Therapeutics Statistics
Share Statistics
DiaMedica Therapeutics has 42.76M shares outstanding. The number of shares has increased by 12.64% in one year.
| Shares Outstanding | 42.76M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 12.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 24.02M |
| Failed to Deliver (FTD) Shares | 1.69K |
| FTD / Avg. Volume | 2.02% |
Short Selling Information
The latest short interest is 175.55K, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 175.55K |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.73% |
| Short Ratio (days to cover) | 3.88 |
Valuation Ratios
The PE ratio is -4.77 and the forward PE ratio is -5.82.
| PE Ratio | -4.77 |
| Forward PE | -5.82 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 1.81 |
| P/FCF Ratio | -4.93 |
| PEG Ratio | n/a |
Enterprise Valuation
DiaMedica Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 19.27, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.27 |
| Quick Ratio | 19.27 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.78 |
| Cash Flow / Debt | -46.82 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.38% and return on capital (ROIC) is -41.42%.
| Return on Equity (ROE) | -0.38% |
| Return on Assets (ROA) | -0.36% |
| Return on Capital (ROIC) | -41.42% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.08M |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 43.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 97.45% in the last 52 weeks. The beta is 1.46, so DiaMedica Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.46 |
| 52-Week Price Change | 97.45% |
| 50-Day Moving Average | 4.6 |
| 200-Day Moving Average | 3.55 |
| Relative Strength Index (RSI) | 59.54 |
| Average Volume (20 Days) | 83.50K |
Income Statement
In the last 12 months, DiaMedica Therapeutics had revenue of $0 and earned -$19.38M in profits. Earnings per share was $-0.6.
| Revenue | 0 |
| Gross Profit | -30.00K |
| Operating Income | -21.27M |
| Net Income | -19.38M |
| EBITDA | -19.31M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.6 |
Balance Sheet
The company has $4.54M in cash and $400.00K in debt, giving a net cash position of $4.14M.
| Cash & Cash Equivalents | 4.54M |
| Total Debt | 400.00K |
| Net Cash | 4.14M |
| Retained Earnings | -115.56M |
| Total Assets | 52.52M |
| Working Capital | 46.47M |
Cash Flow
In the last 12 months, operating cash flow was -$18.73M and capital expenditures -$24.00K, giving a free cash flow of -$18.75M.
| Operating Cash Flow | -18.73M |
| Capital Expenditures | -24.00K |
| Free Cash Flow | -18.75M |
| FCF Per Share | -0.58 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
DMAC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -11.05% |
| FCF Yield | -8.08% |
Analyst Forecast
The average price target for DMAC is $7, which is 28.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 28.9% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Nov 15, 2018. It was a backward split with a ratio of 1:20.
| Last Split Date | Nov 15, 2018 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | 28.35 |
| Piotroski F-Score | 3 |